Targets › AFP
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2027.
Binds copper, nickel, and fatty acids as well as, and bilirubin less well than, serum albumin. Only a small percentage (less than 2%) of the human AFP shows estrogen-binding properties. (UniProt, P02771)
Open in Phaseline: the race on AFP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Ruiliyuan Biotechnology | HRYZ-T102 TCR-T Cell AFP-specific T cell receptor (TCR) engineered T cells | AFP | Phase 1 | Hepatic Cell Carcinoma | Aug 2027 |
Hepatic Cell Carcinoma (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.